Projected Income of $325M to Can-Fite Over the Next 10 Years After Vetbiolix Exercised its Option and Licensed Piclidenoson for Veterinary Osteoarthritis
Can-Fite Biopharma Ltd Sponsored ADR (Israel) (CANF)
NASDAQ:AMEX Investor Relations:
ir.canfite.com
Company Research
Source: GlobeNewswire
The agreement has been signed upon successful conclusion of a clinical study in dogs with osteoarthritis RAMAT GAN, Israel, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that its veterinary partner Vetbiolix exercised its option and signed a development and commercialization agreement with Can-Fite for the development of Piclidenoson for the treatment of osteoarthritis in companion animals including dogs and cats. Vetbiolix concluded successfully a clinical study in dogs with osteoarthritis who were treated orally with piclidenoson for a couple of months period. The arthritis market for companion animals is estimated by Coherent Market Insights to be $3.8 Billion in 2023 and is expected to grow to $6.3 Billion by 2030. Can-Fite and Vetbiolix model that Piclidenoson has the potential t
Show less
Read more
Impact Snapshot
Event Time:
CANF
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CANF alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CANF alerts
High impacting Can-Fite Biopharma Ltd Sponsored ADR (Israel) news events
Weekly update
A roundup of the hottest topics
CANF
News
- Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of HealthGlobeNewswire
- Is Can-Fite BioPharma Ltd. (CANF) The Best Rated Penny Stock To Buy According to Analysts? [Yahoo! Finance]Yahoo! Finance
- Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical StudiesGlobeNewswire
- Solventum's second-quarter profit falls 70% on higher expenses [Yahoo! Finance Canada]Yahoo! Finance Canada
- Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross ProceedsGlobeNewswire
CANF
Sec Filings
- 9/24/24 - Form 6-K
- 9/16/24 - Form 6-K
- 9/9/24 - Form EFFECT
- CANF's page on the SEC website